Schedule 13G ownership disclosure

Amylyx Pharmaceuticals Inc

Security class unavailable · CUSIP: 03237H101

Event date: 2023-11-29

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,176,105
Percent of class
4.7000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-23-005832
Form type
SC 13G
Filer
Amylyx Pharmaceuticals, Inc.
CIK
CIK 1658551
Filed
Dec 11, 2023
Reporting period
Nov 29, 2023
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub